SML2586
(S)-C33
≥98% (HPLC)
别名:
6-[[(1S)-1-(4-Chlorophenyl)ethyl]amino]-1-cyclopentyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, C33(S)
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C18H20ClN5O
化学文摘社编号:
分子量:
357.84
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
O=C1C2=C(N=C(N1)N[C@H](C3=CC=C(C=C3)Cl)C)N(C4CCCC4)N=C2
Biochem/physiol Actions
(S)-C33 [C33(S)] is a potent and selective phosphodiesterase-9A (PDE9A) inhibitor that upregulates cGMP signaling. (S)-C33 protects against cardiac hypertrophy and postpones the transition to heart failure in rat models.
potent and selective phosphodiesterase-9A (PDE9A) inhibitor
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Manna Huang et al.
Molecular pharmacology, 88(5), 836-845 (2015-09-01)
Phosphodiesterase-9 (PDE9) inhibitors have been studied as potential therapeutics for treatment of central nervous system diseases and diabetes. Here, we report the discovery of a new category of PDE9 inhibitors by rational design on the basis of the crystal structures.
Pan-Xia Wang et al.
Acta pharmacologica Sinica, 38(9), 1257-1268 (2017-06-27)
Phosphodiesterase-9A (PDE9A) expression is upregulated during cardiac hypertrophy and heart failure. Accumulating evidence suggests that PDE9A might be a promising therapeutic target for heart diseases. The present study sought to investigate the effects and underlying mechanisms of C33(S), a novel
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持